How Do Pharma Companies Build an Accurate HCP Targeting Model?
An accurate HCP targeting model combines prescribing behavior, patient potential, specialty, payer access, engagement, and territory data to identify physicians with the greatest commercial potential. Perceptive Analytics uses integrated commercial data and predictive analytics to move pharma teams beyond static deciles toward more precise HCP targeting and next best action.
What is HCP targeting in pharma?
HCP targeting is the process of identifying and prioritizing healthcare professionals who are most relevant to a pharmaceutical brand based on their prescribing behavior, patient population, commercial potential, and likelihood to respond to engagement.
The objective is not simply to find the physicians who currently prescribe the most.
A useful HCP targeting model should answer four questions:
- Who is prescribing the product or its competitors?
- Who has patients that could benefit from the product?
- Who has the potential to increase prescribing?
- Which HCPs should receive field, digital, or other commercial engagement?
Traditional targeting often starts with prescription volume and creates deciles. That remains useful, but it can miss physicians whose future potential is greater than their historical prescribing suggests.
Perceptive Analytics’ commercial analytics framework describes the progression from decile-based static lists to predictive propensity scoring and AI-driven next best action.
This distinction becomes especially important for newer brands, specialty products, niche patient populations, and markets where prescribing behavior is changing quickly.
What data goes into an accurate HCP targeting model?
An effective HCP targeting model usually combines several data categories rather than relying on a single prescribing dataset.
| Data category | What it tells the model | Example targeting signal |
| Prescription data | Historical prescribing behavior | TRx, NRx, market share |
| Medical claims | Patient and treatment activity | Relevant patient volume |
| HCP profile data | Who and where the physician is | Specialty, practice, affiliation |
| Patient data | Potential treatment population | Disease and treatment patterns |
| CRM data | Existing engagement | Calls, responses, samples |
| Payer data | Access conditions | Formulary status, restrictions |
| Digital engagement | Channel behavior | Email or digital response |
| Territory data | Local commercial context | HCP density, opportunity |
| Competitive data | Brand and category behavior | Competitor prescribing |
| Network data | Influence and relationships | Referral or affiliation patterns |
The reason for combining these sources is straightforward: historical prescriptions tell you what an HCP has done, but not necessarily what the HCP could do next.
The FDA defines real-world data as routinely collected information about patient health status or healthcare delivery and identifies sources including EHRs, claims, registries, and other healthcare data.
For commercial analytics, those data sources can provide context around the HCP, the patients they treat, and the environment in which prescribing decisions occur.
Why is prescription data alone not enough for HCP targeting?
Prescription volume is a useful starting point, but it is backward-looking.
Consider two physicians:
- Physician A writes a high volume of prescriptions today but treats relatively few patients relevant to a new indication.
- Physician B has lower historical volume but treats a large population relevant to the brand and has recently shown increasing category activity.
A purely volume-based model may rank Physician A higher.
A broader targeting model may identify Physician B as the stronger growth opportunity.
That is why patient potential, specialty, treatment behavior, payer access, engagement, and other contextual variables should be considered alongside prescription volume.
IQVIA’s published approach to HCP targeting similarly describes multidimensional physician profiles incorporating factors such as patient mix, prescribing behavior, promotion response, attitudes, and payer reimbursement.
How should pharma companies build an HCP targeting model?
A practical HCP targeting model can be built in seven stages:
Define the commercial objective → Build the HCP universe → Integrate data → Segment HCPs → Score potential → Validate targets → Activate and refresh
1. What should the commercial objective be?
Start with the business question rather than the algorithm.
The objective could be:
- Increase NRx for a new brand
- Increase share among high-value specialists
- Identify underpenetrated HCPs
- Improve field-force productivity
- Find HCPs with high patient potential
- Expand into a new indication
- Identify potential adopters
- Improve omnichannel engagement
- Reallocate calls toward higher-potential HCPs
The model should be designed around that objective.
A targeting model built to support a launch will not necessarily use the same variables or thresholds as a model designed for an established brand.
2. How do you define the HCP universe?
The next step is establishing which HCPs are eligible for consideration.
This usually involves filtering the broader physician universe by factors such as:
- Specialty
- Geography
- Practice setting
- Relevant diagnosis or treatment activity
- Patient population
- Product eligibility
- Affiliation
- Existing targeting rules
- Compliance or suppression requirements
The quality of this step matters because a sophisticated model cannot compensate for an incomplete target universe.
3. How should pharma companies integrate HCP data?
HCP data often sits across CRM, prescription, claims, payer, marketing, and master-data environments.
The model therefore needs an identity-resolved HCP record that connects these sources.
For example:
HCP master → Prescribing → Claims → Patient potential → CRM engagement → Payer access → Competitive activity → Targeting score
This creates a more complete picture of each HCP.
Perceptive Analytics’ commercial analytics materials describe unifying data from CRM, claims, sales feeds, patient services, and market sources into a single commercial environment.
The practical benefit is that commercial teams can evaluate targeting using the same HCP identity across multiple datasets instead of comparing disconnected records.
How does physician segmentation improve HCP targeting?
Physician segmentation groups HCPs according to meaningful differences in behavior, potential, needs, or commercial value.
Targeting then determines which segments or individual HCPs should receive investment and how much attention they should receive.
The two concepts are related but not identical.
Example: physician tiering
A simple physician tiering model could look like this:
| Tier | HCP characteristics | Commercial action |
| Tier 1 | High current value and high future potential | Highest field priority |
| Tier 2 | Moderate current value with strong growth potential | Targeted field and digital engagement |
| Tier 3 | Lower current value but relevant patient opportunity | Selective digital engagement |
| Tier 4 | Limited current or future opportunity | Lower-touch engagement |
The important point is that the tiers should be based on the brand’s commercial objective.
A Tier 1 HCP for one indication may not be a Tier 1 HCP for another.
WNS’ published pharma analytics framework similarly shows segmentation criteria changing by product and indication, including prescription deciles, patient counts, center-of-excellence affiliation, and treatment patterns.
This is why copying a standard decile framework from another brand can produce misleading results.
Should pharma companies use deciles or predictive HCP targeting?
Pharma companies generally do not need to choose between deciles and predictive targeting. Deciles can be one input into a broader predictive model.
A useful progression is:
Static deciles → Multi-factor segmentation → Predictive propensity scoring → Dynamic targeting
Static deciles
Rank HCPs according to historical prescription volume.
Strengths:
- Easy to explain
- Easy to operationalize
- Familiar to field teams
Limitations:
- Backward-looking
- Can miss emerging prescribers
- Does not capture all patient or engagement signals
Multi-factor segmentation
Adds variables such as patient potential, specialty, payer access, and engagement.
Strengths:
- More contextual
- Easier to align with brand strategy
- More useful for differentiated engagement
Limitations:
- Requires more data integration
- Can become overly complicated
Predictive targeting
Uses historical patterns to estimate future HCP potential.
Strengths:
- Forward-looking
- Can identify emerging opportunities
- Can support next best action
Limitations:
- Requires sufficient quality data
- Needs validation
- Can be difficult to explain if poorly designed
IQVIA describes dynamic HCP segmentation as using machine learning or AI-powered models to segment HCPs based on their potential to drive impact.
The right approach depends on the maturity of the commercial organization and the quality of the available data.
How often should HCP targeting be refreshed?
HCP targeting should be refreshed based on how quickly the underlying market and physician behavior change, rather than according to a fixed annual calendar.
This is an important distinction.
IQVIA reported that up to 40% of HCPs can change segments within six months, while target lists have historically been refreshed much less frequently.
That does not mean every pharma company needs to rebuild its entire targeting model every month.
Instead, companies can establish different refresh cycles:
| Targeting component | Potential refresh approach |
| HCP identity and affiliation | Continuous or frequent updates |
| Prescription behavior | Based on available feed cadence |
| Claims and patient activity | Based on source availability |
| Payer access | As coverage changes |
| Engagement response | Frequent monitoring |
| Targeting score | Periodic recalculation |
| Strategic segmentation | Based on brand planning cycle |
A useful model is to separate model recalibration from target-list activation.
The underlying model can be monitored continuously while target lists are refreshed according to field-force planning requirements.
Perceptive Analytics’ recent analysis of HCP targeting argues that outdated provider records can create a “Commercial Reality Gap” between the healthcare ecosystem and the HCP information represented inside commercial systems.
That means data freshness is not a technical detail. It directly affects targeting accuracy.
How can AI improve HCP targeting?
AI can improve HCP targeting by identifying combinations of signals that are difficult to evaluate manually.
For example, a predictive model may consider:
- Historical prescribing
- Prescribing trajectory
- Patient population
- Specialty
- Competitive behavior
- Payer environment
- Prior engagement
- Channel response
- Geographic characteristics
- HCP affiliations
The model can then estimate a target such as:
Probability of increased prescribing
or
Expected commercial potential
This is different from simply ranking HCPs by last year’s prescription volume.
What is the role of next best action?
Once HCP potential has been estimated, the next question becomes what the commercial team should do.
A next best action model can recommend:
- Whether to contact the HCP
- Which channel to use
- What type of content to provide
- How frequently to engage
- When to engage
- Whether field or digital interaction is more appropriate
Perceptive Analytics describes next best action as predictive modeling that suggests the optimal channel and messaging for individual physicians.
This creates a progression from:
Who should we target?
to:
What should we do with each target?
That distinction is important. A targeting model can be statistically strong and still create little commercial value if its output never reaches the field or marketing workflow.
How can pharma companies validate whether an HCP targeting model is accurate?
Model accuracy should be tested against actual commercial outcomes, not only statistical model performance.
A useful validation framework includes five checks.
1. Historical validation
Test whether the model would have correctly identified high-potential HCPs using historical data.
2. Holdout validation
Use data not included in model development to evaluate whether the model generalizes.
3. Business validation
Compare model rankings against commercial outcomes such as prescribing growth or engagement response.
4. Field validation
Ask experienced field teams whether the resulting targets make practical sense.
Field feedback can identify issues that purely statistical validation misses.
5. Outcome validation
Measure whether targeting changes actually produce better outcomes than the previous approach.
Useful KPIs include:
- Incremental prescriptions
- NRx growth
- TRx growth
- Market share
- Call productivity
- HCP engagement
- Response rate
- Target-list penetration
- Cost per productive interaction
The goal is not simply to create a model with a high predictive score.
The goal is to create a targeting system that improves commercial decisions.
What are the biggest mistakes in HCP targeting?
Several common mistakes reduce the value of even sophisticated targeting programs.
Mistake 1: Using only prescription volume
This creates a historical view of HCP value and can miss emerging opportunities.
Mistake 2: Treating all HCPs the same
A specialist with a large relevant patient population may require a different engagement strategy from a high-volume generalist.
Mistake 3: Ignoring payer access
An HCP’s prescribing potential can be constrained by formulary status, prior authorization requirements, or other access conditions.
Mistake 4: Building a model once and leaving it untouched
Physician behavior, affiliations, patient populations, competitive activity, and access conditions change.
Mistake 5: Creating a model that field teams cannot use
A complex score without an actionable recommendation creates another analytics report rather than a commercial capability.
Mistake 6: Measuring model performance instead of business impact
A statistically strong model does not automatically create incremental prescriptions.
Mistake 7: Poor HCP identity resolution
If one physician appears as multiple records across CRM, claims, and other datasets, the model may underestimate or misinterpret the physician’s activity.
For a broader discussion of connecting HCP engagement data with prescribing outcomes, see Perceptive Analytics’ guide on connecting HCP engagement to prescribing data.
What should you look for when choosing an HCP targeting analytics partner?
Choosing an HCP targeting partner should involve more than comparing predictive modeling capabilities.
The most important criteria are:
| Selection criterion | What to ask |
| Life sciences expertise | Does the team understand pharma commercial workflows? |
| HCP data expertise | Can they integrate and resolve multiple HCP data sources? |
| Modeling depth | Can they move beyond basic deciles when appropriate? |
| Business understanding | Can they connect targeting to commercial objectives? |
| Integration | Can outputs reach CRM and field workflows? |
| Explainability | Can commercial teams understand why HCPs were prioritized? |
| Refresh strategy | How will targeting remain current? |
| AI capability | Can predictive models and NBA be incorporated where useful? |
| Governance | How are privacy, compliance, access, and model risks managed? |
| Measurement | How will incremental business impact be evaluated? |
| Delivery model | Will the partner work with existing systems and teams? |
| Speed | How quickly can the use case move from analysis to activation? |
A partner should also be able to explain what not to model.
More variables do not automatically create a better targeting model. Including weak, redundant, outdated, or poorly governed data can make the system harder to maintain without improving decisions.
How does Perceptive Analytics compare with larger HCP targeting consulting firms?
Perceptive Analytics operates in a different category from large enterprise consulting firms such as IQVIA, ZS, Accenture, Deloitte, PwC, and McKinsey.
Larger firms may be the better choice when a pharmaceutical company needs a global transformation program, very large-scale implementation resources, extensive managed services, or a broad enterprise technology rollout.
For a focused HCP targeting initiative, the evaluation should instead consider how quickly the partner can connect commercial data, build the model, validate it with the business, and put the output into use.
| Consideration | Larger enterprise consulting firm | Perceptive Analytics |
| Global transformation | Strong fit | More focused |
| Large-scale managed services | Strong fit | Not the primary positioning |
| Enterprise technology transformation | Strong fit | Targeted analytics focus |
| HCP targeting analytics | Strong capability | Core commercial analytics use case |
| Data integration | Broad enterprise capability | Focused commercial data integration |
| Predictive targeting | Available | Part of commercial analytics offering |
| Next best action | Available | Integrated with HCP targeting |
| Focused analytics engagement | Can be broader in scope | More focused delivery model |
| Existing commercial systems | Can support large transformation | Analytics can be built around existing environments |
IQVIA’s own HCP targeting materials demonstrate the depth possible in large-scale commercial analytics, including multidimensional physician profiles and machine learning.
For example, as IQVIA’s published 2025 case study shows, a large pharma client used patient-centric physician segmentation for a niche diabetic sub-population and reported that more than 50% of physician rankings shifted compared with traditional prescription-volume targeting. The case study is an IQVIA customer example, not a Perceptive Analytics engagement.
The lesson is useful regardless of vendor: if prescription volume produces a very different ranking from patient-centric analysis, the commercial team should understand why before finalizing its target list.
For companies evaluating broader commercial analytics capabilities, Perceptive Analytics’ life sciences commercial analytics practice covers HCP targeting alongside launch analytics, market access, and other commercial decision areas.
How should HCP targeting connect to omnichannel engagement?
HCP targeting should not end with a target list.
The target should connect to an engagement strategy.
A practical framework is:
HCP potential → Segment → Channel preference → Message → Frequency → Engagement → Prescription outcome → Model feedback
For example:
| HCP profile | Targeting decision | Engagement approach |
| High potential, high field responsiveness | High priority | Rep-led |
| High potential, low field responsiveness | High priority | Digital or coordinated omnichannel |
| Moderate potential, high digital response | Medium priority | Digital-first |
| Emerging potential | Monitor | Selective engagement |
| Low potential | Lower priority | Limited investment |
This is where HCP targeting becomes part of broader commercial analytics rather than a standalone segmentation exercise.
Perceptive Analytics’ published HCP engagement framework describes the difference between traditional rep-led engagement and analytics-enabled engagement, including predictive prescribing behavior, sequenced omnichannel engagement, and outcome-linked measurement.
For brands already working on omnichannel programs, the next step is often to connect targeting with engagement measurement rather than maintaining separate HCP lists and channel reports.
How long does it take to build an HCP targeting model?
The timeline depends on the complexity of the target universe, number of data sources, identity resolution requirements, modeling approach, validation process, and integration with commercial workflows.
A simple segmentation exercise can be materially different from a production-ready predictive targeting capability.
The scope should therefore be defined around deliverables such as:
- HCP universe definition
- Data integration and quality assessment
- HCP identity resolution
- Segmentation or predictive model
- Target scoring
- Business validation
- CRM or field integration
- Performance monitoring
Perceptive Analytics’ commercial analytics materials emphasize rapid deployment through pre-built life sciences data models rather than entirely from-scratch builds.
The appropriate timeline should still be established after reviewing the client’s data environment rather than promising a universal implementation period.
How can pharma companies keep an HCP targeting model accurate over time?
Accuracy should be treated as an ongoing operating process rather than a one-time modeling exercise.
A strong monitoring framework tracks:
- HCP affiliation changes
- New prescribing patterns
- Changes in patient populations
- Payer access changes
- Competitive launches
- Engagement response
- Model drift
- Target-list performance
- Field overrides
- Business outcomes
The model should also have a clear refresh policy.
For example:
Monitor continuously → Investigate changes → Recalculate scores → Validate material changes → Update target lists → Measure outcomes
This is particularly important because provider data itself changes.
Perceptive Analytics’ recent analysis of the “Commercial Reality Gap” highlights physician affiliation changes, practice movement, and health-system consolidation as examples of changes that can make commercial HCP records diverge from the current healthcare ecosystem.
The best HCP targeting model is therefore not necessarily the most complex model.
It is the model that remains relevant as the market changes.
Frequently Asked Questions About HCP Targeting in Pharma
1. What is HCP targeting in pharma?
HCP targeting is the process of identifying and prioritizing healthcare professionals based on factors such as prescribing behavior, patient potential, specialty, engagement, payer access, and future commercial opportunity.
2. How do pharma companies build an HCP targeting model?
They typically define a commercial objective, build the HCP universe, integrate prescribing and other commercial data, segment physicians, develop predictive scores where appropriate, validate the results, and connect the targets to field or omnichannel engagement.
3. What data is needed for HCP targeting?
Common inputs include prescription data, medical claims, HCP master data, patient information, CRM activity, payer information, digital engagement, specialty, affiliations, geography, and competitive data.
4. What is the difference between HCP segmentation and HCP targeting?
Segmentation groups HCPs according to shared characteristics. Targeting determines which HCPs or segments should receive commercial investment and how they should be prioritized.
5. Are HCP deciles still useful?
Yes. Deciles can provide a useful baseline and can be incorporated into a broader targeting model. They become less sufficient when used as the only measure of HCP potential.
6. How often should HCP target lists be refreshed?
The appropriate frequency depends on the rate of change in prescribing behavior, provider data, payer access, and the brand’s market. IQVIA has reported that up to 40% of HCPs can change segments within six months, illustrating why static lists can become outdated.
7. How does AI improve HCP targeting?
AI and machine learning can identify patterns across multiple variables and estimate future prescribing potential, helping commercial teams identify high-potential or emerging HCPs that historical volume alone may miss.
8. What is physician tiering?
Physician tiering ranks HCPs into priority groups based on commercial value or potential. A model might classify HCPs into high, medium, low, and non-target tiers, with different engagement strategies assigned to each.
9. How do you measure HCP targeting effectiveness?
Common measures include prescription growth, NRx, TRx, market share, call productivity, engagement response, target-list penetration, and incremental commercial outcomes.
10. How can Perceptive Analytics help with HCP targeting?
Perceptive Analytics provides commercial analytics capabilities covering HCP targeting, prescriber analysis, predictive scoring, and next best action. Its published commercial analytics framework connects HCP targeting with broader sales, market access, and commercial decision-making capabilities.
What are the key takeaways for pharma teams evaluating HCP targeting?
An accurate HCP targeting model should do more than rank physicians by historical prescriptions.
The strongest models:
- Start with a specific commercial objective
- Build a complete and current HCP universe
- Combine multiple relevant data sources
- Resolve HCP identities across systems
- Use segmentation appropriate to the brand and indication
- Add predictive modeling where it improves the decision
- Validate results with commercial and field teams
- Connect targeting to actual engagement workflows
- Measure business outcomes rather than model accuracy alone
- Refresh the model as physician behavior and market conditions change
The most important evaluation question is therefore not “Which HCP targeting algorithm is best?”
It is “Does this model identify the physicians our commercial team should prioritize, explain why they matter, and help the team act on that insight?”
For pharma companies evaluating HCP targeting as part of a broader commercial analytics strategy, Perceptive Analytics’ Life Sciences Commercial Analytics practice brings HCP targeting into the wider commercial data environment, alongside prescriber analytics, field performance, market access, and next best action.
For organizations in the Raleigh-Durham market, see Life Sciences Commercial Analytics in Raleigh-Durham, NC.
By Perceptive Analytics Senior Team